1, R&D strength analysis:
Clinical filing of stem cell drugs;
2, industrial chain analysis:
Enterprise layout, national layout and industrial system;
3, battery quality standards:
Qualification certification, preparation standards, quality control and process system construction of stem cell banks and preparation centers;
3. Corporate reputation:
Safety accident investigation, customer evaluation, etc.
4. Highlight industry contributions:
Industrial innovation, industry standard formulation, historical position, future value evaluation, and world influence;
The first Beko creature
Reasons for listing
It is a representative enterprise in the field of stem cells in China, representing China's stem cell field and international dialogue for a long time, and successive central leaders have focused on enterprises. At present, it has covered 7 countries around the world, covering stem cell banks and preparation centers in 8 provinces across the country.
Chinese mainland is the first enterprise that has passed the AABB (Advanced Alliance for Cell Therapy and Blood Transfusion) standard certification, including hematopoietic stem cells from human umbilical cord, mesenchymal stem cells from human umbilical cord, mesenchymal stem cells from human placental decidua and immune cells from human peripheral blood. And participated in the formulation of AABB standard for "human umbilical cord mesenchymal stem cells".
20 15 participated in the formulation of Shenzhen cell bank and preparation center standards, the evaluation of cell preparation personnel titles, and the construction of a third-party "cell quality testing platform", which made indelible contributions to establishing China's stem cell quality standards and clarifying industry norms.
Biological clinical application items of Beijing Branch:
A randomized, double-blind, parallel-controlled multicenter study of umbilical cord mesenchymal stem cells in the treatment of lupus nephritis: Zhongshan Hospital affiliated to Fudan University
A randomized, blind, parallel and controlled multicenter study of umbilical cord mesenchymal stem cells in the treatment of lupus nephritis. Nanjing Gulou Hospital (second prize of National Science and Technology Progress Award)
Randomized parallel controlled clinical study on the safety and effectiveness of different transplantation routes of human umbilical cord mesenchymal stem cells in the treatment of type 2 diabetes mellitus: Peking University Shenzhen Hospital
Clinical application of umbilical cord mesenchymal stem cells in the treatment of moderate and severe refractory systemic lupus erythematosus: Anhui Provincial Hospital
Clinical study of umbilical cord mesenchymal stem cells combined with modern rehabilitation in the treatment of cerebral palsy in children in Taihe Hospital
Prospective randomized controlled clinical study on the treatment of diabetic foot wounds by injection of human umbilical cord mesenchymal stem cells: Affiliated Hospital of Xuzhou Medical University
Second place Zhongyuan Concord
Reasons for listing
China Stem Cell Main Board represents a listed company, and after listing, it laid out stem cells and cell therapy plates on a large scale. With advanced cell technology and national cell resource storage network, the storage capacity of cells has exceeded 300,000 copies, and it is one of the important research and development and transformation bases of cell technology products in China. Through capital advantage, it is becoming the main force of China Biomedical Industry Group.
Central Plains Sheikh Clinical Application Project:
Clinical study of human umbilical cord mesenchymal stem cells in the treatment of neuropathic pain
Huazhong University of Science and Technology Tongji Medical College Affiliated Union Medical College Hospital
Randomized double-blind controlled clinical study of human umbilical cord mesenchymal stem cells in the treatment of hepatitis B cirrhosis (compensatory stage)
People's Hospital of Wuhan University
A randomized double-blind controlled clinical study on human umbilical cord mesenchymal stem cells (UC-MSC) delaying the progression of renal function in patients with chronic kidney disease (CKD3 stage 3 and 4)
Tongji hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology
Clinical study on the effect of umbilical cord mesenchymal stem cells on liver regeneration in patients with decompensated hepatitis B cirrhosis
The First Hospital of Lanzhou University
A single-center, open clinical study of injection of human dental pulp mesenchymal stem cells in the treatment of moderate and severe plaque psoriasis vulgaris (stage ⅰ/ⅱ A): First Affiliated Hospital of Jilin University.
Third place Jia
Reasons for listing
Jiachenhong is a high-tech enterprise recognized by Beijing Science and Technology Commission, specializing in technical consultation and technical training services for cryopreservation of umbilical cord blood hematopoietic stem cells. The "Beijing Umbilical Cord Blood Hematopoietic Stem Cell Bank" jointly established by Peking University Institute of Hematology from 65438 to 0996 is an early and large-scale umbilical cord blood hematopoietic stem cell bank in China, which has provided many successful transplant cases. At present, the cord blood bank stores nearly 10000 copies of cord blood, and the public blood bank has provided 64 copies of cord blood unrelated to hematopoietic stem cell transplantation for more than 60 patients, with a success rate of 84%. It is a leading enterprise focusing on "hematopoietic stem cell transplantation" in China at present.
Fourth place: Sibiman
Reasons for listing
Cyberman Biotechnology Group (NASDAQ CBMG) is a cell therapy company registered in Delaware and listed on NASDAQ Stock Exchange, focusing on the China market. CBMG is developing adult stem cells for regenerative medicine.
Siberian clinical archiving project:
CBMG completed the IIb trial of autologous adipose-derived mesenchymal progenitor cells (haMPC) in the treatment of knee osteoarthritis (KOA) in China.
China phase I trial of allogeneic human adipose-derived mesenchymal progenitor cells in the treatment of knee osteoarthritis.
IND:
Autologous human adipose-derived mesenchymal progenitor cells injection 1.
CBM-ALAM. 1 Allogeneic human adipose-derived mesenchymal progenitor cells inject new drugs, 1.
Fifth place: Rong Hui Renhe
Reasons for listing
Shenzhen Ronghui Renhe Life Science and Technology Co., Ltd. is an innovative enterprise that invests and operates industrial project ecosystem in the field of life and life sciences.
Renhe group, Rong Hui has launched an innovative bio-industry ecological platform, which divides enterprises into two major business groups: biomedicine and life and health. Biomedical Experimental Group has established "Central Laboratory, CDMO, Management Committee, CRO, GCP, GLP" centers in Chengdu to complete drug declaration through drug acceleration and venture capital. Life and Health Enterprise Group has established an innovative service system with "Ark of Life" as the core. It is an innovative enterprise with innovative layout in the industry.
At present, the industrial ecological circle projects that have been put into production and under construction in renhe group mainly include:
① Shenzhen University/Beike Rong Hui Life Industry Technology Innovation Center, Industry-University-Research Medical Benchmarking Project;
2 Rong Hui Intelligent is responsible for the research and development and production of cell preparation robots, and has completed the first generation of cell preparation robot products;
③ Beike Rong Hui (Dongxiang) Company built the world's largest cell bank in Dajian Industrial Park;
④ Guizhou Beike and Zunyi Beike merged to build AABB-certified "Beike (Guiyang) Comprehensive Cell Bank and Cell Preparation Center" in Guanshan Lake in Guiyang and Honghuagang in Zunyi, which has been put into operation;
⑤ Taohuaxi Life Valley, a medical tourism and stem cell anti-aging center built in Meitan, Zunyi, was approved by the National Health Planning Commission, Development and Reform Commission and other five ministries and commissions to become a national health tourism demonstration base;
⑥ School of Life and Health Management, which cooperated with Guizhou University of Finance and Economics, began to recruit undergraduates on 20 17;
⑦ "Chengdu Langgu", which is controlled by renhe group, chairman of Rong Hui, and cooperated with Wei Yuquan, an academician of the State Key Laboratory of Biotherapy of Sichuan University and the former winner of the FDA Lifetime Achievement Award, is located in the frontier medical park of Chengdu High-tech Zone, and is the base of cell therapy research, clinical experiment and cell drug production in renhe group, Rong Hui.
⑧ Life Ark Laboratory is an innovative scientific research project of synthetic biology based on adolescent biological research and education under renhe group.
RIT:
Therapeutic effect of allogeneic placental amnion stem cells on premature ovarian failure: Affiliated Hospital of Zunyi Medical College
Study on the treatment of knee joint degeneration with allogeneic placental amniotic stem cells and exosomes: Affiliated Hospital of Zunyi Medical College
IND:
CD34+ Japan TRI Institute for Patients with Severe Limb Ischemia
Comet treatment of severe ocular surface diseases in Japan TRI Institute
Sixth place: Guangdong cord blood bank.
Reasons for listing
With its advanced technology, professional personnel, advanced equipment, reliable quality and remarkable achievements, it has obtained the national high-tech enterprise certification, has the technical ability to extract and prepare a variety of stem cells, and has carried out scientific research cooperation with many universities and medical institutions on umbilical cord blood.
Guangdong Umbilical Cord Blood Bank obtained AABB system-wide certification, including the procurement, acquisition and storage of umbilical cord blood.
Seventh place: Boya stem cells
Reasons for listing
Its four brand plates, Boya Stem Cell, Perceptual Medicine, Perceptual Medicine and Apollo Limu, include multi-business channels such as cell storage and clinical application, automated cell medical equipment, cell therapy technology research and development, animal seed technology research and development and industrial application.
Boya stem cell bank has passed AABB certification, including the whole system of obtaining, processing and storing mesenchymal stem cells from human umbilical cord.
Boya clinical archiving project:
Boya has a phase III clinical trial of autologous stem cell technology approved by FDA, which is used to treat severe limb ischemia (CLI).
Boya has FDA-approved autologous cell therapy for refractory wounds.
Eighth place: Han United
Reasons for listing
Established in 2007, Beijing Han Shi United Biotechnology Co., Ltd. (hereinafter referred to as "Han Shi United") is a high-tech enterprise recognized by the state. As a pioneer in the stem cell industry, Han takes the healthy development of human life as his own responsibility, takes stem cell regenerative medicine technology as the core, and gradually forms a medical and health platform led by the research and development of new stem cell drugs, perinatal stem cell storage and integrated services, aiming at creating a closed loop of the entire industrial chain of stem cell regenerative medicine. Cell bank business has been launched in many provinces and cities in China.
Korean joint clinical application project:
Treatment of diabetic foot ulcer with human placenta mesenchymal stem cell gel Beijing Tongren Hospital/Wuhan Zhongnan Hospital/First Affiliated Hospital of Nanchang University
Injection of highly active human umbilical cord mesenchymal stem cells for severe lower limb ischemia, Reims University Medical Center, France.
Intractable acute graft-versus-host disease of mesenchymal stem cells (umbilical cord) for injection, Union Medical College Hospital, Fujian Medical University (Ansai, Tianjin)
Ninth place: Jiuzhitang Ke Mei
Reasons for listing
Jiuzhitang Ke Mei (Beijing) Cell Technology Co., Ltd. (Stemedica) and its partners have conducted eight clinical trials of stem cells in the United States, namely ischemic stroke, skin photoaging, non-ischemic chronic heart failure, Alzheimer's disease, traumatic brain injury, heart failure requiring LVAD implantation, acute myocardial infarction and lung injury caused by COVID-19. Among them, ischemic stroke and chronic heart failure have completed clinical phase IIa trials and published many high-level academic papers, while the clinical trials of Alzheimer's disease, in addition, Stemedica has conducted 1 1 in Switzerland, Kazakhstan, Mexico, China and other countries, among which the clinical trial of it-hMSC produced by Stemedica in the treatment of acute myocardial infarction has been completed, and on 201.
Clinical record items:
Ischemia-tolerant human allogeneic bone marrow mesenchymal stem cells
The first clinical trial approved by FDA to treat Alzheimer's disease with stem cells.
IND:
A new drug for ischemic tolerance of human allogeneic bone marrow mesenchymal stem cells 1
Tenth place: Celera
Reasons for listing
Guangzhou Celera Stem Cell Technology Co., Ltd. (stock code: 83 1049) is the first stem cell listed company in China New Third Board.
Guangdong (Celera) regional cell preparation center (hereinafter referred to as the preparation center) is a provincial-level regional cell preparation center jointly approved by Guangdong Development and Reform Commission, Provincial Science and Technology Department, Provincial Health Planning Commission and Provincial Food and Drug Administration, and built by Celera stem cells.